"We are pleased with the results to date in the clinical work being carried-out by Pantarhei Bioscience, our Pill-Plus licensee," said Stephen M. Simes, BioSante's president & CEO. "We look forward to additional clinical results in the Pill-Plus' development program in the next 12 months. These efforts by Pantarhei in women taking OCs, in addition to our Phase III LibiGel clinical program in the treatment of FSD in menopausal women, highlight BioSante as a leader in women's sexual health in the United States."

The Pill-Plus United States patents for oral use are licensed by BioSante to Pantarhei Bioscience, a Netherlands-based pharmaceutical company, for development and marketing in the United States. BioSante retains rights to the Pill-Plus for transdermal development and marketing.

In addition to this completed study, Pantarhei is engaged in several other Phase II/III clinical studies of the Pill-Plus. The objectives of the other studies are many, including investigating the effect of restoration of testosterone levels by oral DHEA on the pharmacokinetics of oral contraceptives and the effects of adding DHEA to oral contraceptive treatment on sexual function and other measures including mood, muscle mass and fat and bone parameters.

SOURCE BioSante Pharmaceuticals, Inc.